An interventional study of ACT Lung Health Intervention in Smoking Cessation, Smoking Behaviors and Smoking, Tobacco, sponsored by Dana-Farber Cancer Institute. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 921 studies in Smoking Cessation with a site in United States — 98 open to participants now, 127 under way, 7 of them phase 3. Smoking Cessation · United States.
Among the 921 studies in Smoking Cessation with a site in United States, this one is the 648th largest by planned enrollment of the 873 interventional ones that give a count, is one of 28 that started in 2025, is one of 513 with no phase, reaches primary completion later than 24 of the 126 other live ones, and was the 870th registered.
1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.
Browse Smoking Cessation studies →98 of the 921 studies in Smoking Cessation with a site in United States are open now. Recruiting first, the newest first:
Seattle Institute for Biomedical and Clinical Research · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 21+ · Healthy volunteers
Axsome Therapeutics, Inc. · Sites in United States
Ages 18–65
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
921 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 68 · Phase 2 137 · Phase 3 91 · Phase 4 99
First in 1996; this study’s year is marked. 28 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 163 across 1,425 interventional studies indexed under Smoking Cessation.
Median enrollment 148 across the 873 interventional studies, 200 across the 45 observational. Of the 756 that completed or were terminated, 377 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 921 have an industry lead sponsor. The 10 most frequent:
Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
Dana-Farber Cancer Institute has 4 studies filed under Smoking Cessation — fewer than ten, so there is no comparison to draw.
56 of the studies in Smoking Cessation with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04176172Phase 3Abramson Cancer Center at Penn MedicineOptimizing Tobacco Use Treatment for PLWHA | 2026-11-30 |
| NCT05732272Phase 3University of Kansas Medical CenterImproving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment | 2027-01-31 |
| NCT06945120Dana-Farber Cancer InstituteACT Lung Health Intervention: Phase Two | 2026-11-30 |
| NCT00591175Memorial Sloan Kettering Cancer CenterA Randomized Clinical Trial Assessing Smoking Cessation Interventions In Dental Clinic Smokers | 2026-12 |
| NCT06837220University of ChicagoImplementation of Tobacco Cessation Programming at Community Behavioral Health Sites | 2026-12 |
Add all 56 to your calendar (.ics) → With an account.
Among the 921 studies in Smoking Cessation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.
This two-arm stratified randomized clinical trial is to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.
Participants will be randomized into one of two groups: Group A: ACT Lung Health Intervention versus Group B: Standard Care. Randomization means a participant is placed into a study group by chance.
The research study procedures include screening for eligibility, questionnaires, and saliva tests.
It is expected participation in this study will last about 6 months.
About 50 participants are expected to take part in this research study.
The National Cancer Institute is providing funding for this trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
We will not include any of the following special populations:
Participants will be randomized 1:1 in blocks, stratified by ethnicity and readiness to quit smoking and will complete: * Baseline assessment * Eight telephone or video counseling sessions over 8 weeks * Nicotine replacement therapy (NRT) patches, gums and lozenges will be provided * Written educational materials on lung cancer screening will be provided * Assessments at 1, 3, and 6 months * 3 month saliva test * 6 month saliva test
Behavioral: ACT Lung Health Intervention
Participants will be randomized 1:1 in blocks, stratified by ethnicity and readiness to quit smoking and will complete: * Baseline assessment * Six telephone or video counseling sessions over 8 weeks * Nicotine replacement therapy (NRT) patches, gums and lozenges will be provided * Written educational materials on lung cancer screening will be provided * Assessments at 1, 3, and 6 months * 3 month saliva test * 6 month saliva test
An Asian culture-tailored lung health intervention, which includes individual counseling sessions, family coaching, provision of nicotine replacement therapy (NRT) in the form of patches, lozenges, or chewing gum, and educational materials about low-dose computed tomography (LDCT) for lung cancer screening. The eight weekly, counseling sessions with study staff will be conducted via phone call or the Zoom web-conferencing platform.
Also known as: Asian Culturally Tailored Lung Health (ACT) Intervention
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence at 6 Months (Group A)
The proportion of participants who have not smoked cigarettes (not even a puff) in the past 7 days at the 6-month follow-up, verified biochemically using salivary cotinine testing. Participants reporting abstinence and not using nicotine replacement therapy (NRT) will perform a salivary cotinine test observed via video call. Cotinine levels ≤3 ng/mL will confirm abstinence.
Time frame: 6 months post-baseline assessment
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence at 6 Months (Group B)
The proportion of participants who have not smoked cigarettes (not even a puff) in the past 7 days at the 6-month follow-up, verified biochemically using salivary cotinine testing. Participants reporting abstinence and not using nicotine replacement therapy (NRT) will perform a salivary cotinine test observed via video call. Cotinine levels ≤3 ng/mL will confirm abstinence.
Time frame: 6 months post-baseline assessment
Change in Number of Cigarettes Smoked per Day from Baseline to 6 Months (Group A)
The mean change in the number of cigarettes smoked by participants per day from baseline to 6 months post-baseline.
Time frame: Baseline and 6 months post-baseline assessment
Change in Number of Cigarettes Smoked per Day from Baseline to 6 Months (Group B)
The mean change in the number of cigarettes smoked by participants per day from baseline to 6 months post-baseline.
Time frame: Baseline and 6 months post-baseline assessment
Self-Reported 7-Day Point Prevalence Smoking Abstinence at 3 Months (Group A)
The proportion of participants who self-report not smoking cigarettes (not even a puff) in the past 7 days at the 3-month follow-up.
Time frame: 3 months post-baseline assessment
Self-Reported 7-Day Point Prevalence Smoking Abstinence at 3 Months (Group B)
The proportion of participants who self-report not smoking cigarettes (not even a puff) in the past 7 days at the 3-month follow-up.
Time frame: 3 months post-baseline assessment
Self-Reported 7-Day Point Prevalence Smoking Abstinence at 6 Months (Group A)
The proportion of participants who self-report not smoking cigarettes (not even a puff) in the past 7 days at the 6-month follow-up.
Time frame: 6 months post-baseline assessment
Self-Reported 7-Day Point Prevalence Smoking Abstinence at 6 Months (Group B)
The proportion of participants who self-report not smoking cigarettes (not even a puff) in the past 7 days at the 6-month follow-up.
Time frame: 6 months post-baseline assessment
Completion of Lung Cancer Screening with Low-Dose Computed Tomography (LDCT) at 6 Months (Group A)
The proportion of participants eligible for lung cancer screening who have completed lung cancer screening using LDCT within 6 months after baseline assessment. Completion will be verified by self-report and/or by obtaining a copy of the LDCT results from participants.
Time frame: Within 6 months post-baseline assessment
Completion of Lung Cancer Screening with Low-Dose Computed Tomography (LDCT) at 6 Months (Arm B)
The proportion of participants eligible for lung cancer screening who have completed lung cancer screening using LDCT within 6 months after baseline assessment. Completion will be verified by self-report and/or by obtaining a copy of the LDCT results from participants.
Time frame: Within 6 months post-baseline assessment
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.
Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 12 months is below that.
Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dana-Farber Cancer Institute →